News
The Centers for Disease Control and Prevention's vaccine advisory committee is set to meet for the first time since Health ...
The meeting, scheduled for June 25-26, will review existing data and vote on RSV and influenza vaccines, along with ...
CSL shares are down nearly 20% over 5 years. Is the stock undervalued today? Let's see what JP Morgan and other experts think.
Fluad is an influenza vaccine that includes an adjuvant to enhance immunity and was approved by the Ministry of Food and Drug Safety for use in individuals aged 65 and older in September 2022.
Fluad - The adjuvanted influenza vaccine was approved by the FDA in February 2020 for people aged six months and older. The three vaccines combined brought in sales of $1.72 billion in 2024.
Fluad - The adjuvanted influenza vaccine was approved by the FDA in February 2020 for people aged six months and older. The three vaccines combined brought in sales of $1.72 billion in 2024.
Are CSL shares undervalued or will they continue to underperform? The post What's JP Morgan's price target on CSL shares?
Fluad - The adjuvanted influenza vaccine was approved by the FDA in February 2020 for people aged six months and older. The three vaccines combined brought in sales of $1.72 billion in 2024.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results